Ipamorelin

Ipamorelin is a synthetic pentapeptide that acts on the ghrelin receptor to trigger a pulse of growth hormone. Its distinguishing feature is selectivity — it raised GH without the cortisol and prolactin rises seen with older secretagogues. Selectivity is a pharmacological advantage, not a demonstrated clinical benefit: the uses it is promoted for have not been established in human trials. In Australia it is unregistered, prescription-only, and prohibited in sport.

What ipamorelin is

Ipamorelin is a synthetic pentapeptide — five amino acids — classed as a growth hormone secretagogue (GHS): a compound that prompts the pituitary to release growth hormone (GH) rather than supplying GH from outside.

It belongs to a family that began with the growth-hormone-releasing peptides GHRP-6 and GHRP-2. Those compounds worked, but they were untidy: they raised GH and also raised cortisol, ACTH and prolactin. Ipamorelin was developed to isolate the GH effect, and when Raun and colleagues described it in the European Journal of Endocrinology in 1998 it was presented as the first selective growth hormone secretagogue. That is genuine pharmacology and its historical significance.

What it is not is an approved medicine: it was investigated clinically and never reached registration in Australia or comparable markets. Where it is used here, it is as a compounded, prescription-only preparation. It is most often discussed alongside CJC-1295, which acts on a different receptor entirely — see our guide to GH peptides in Australia.

How it works

The ghrelin receptor is the target. Ghrelin is a hormone released mainly by the stomach, best known as the "hunger hormone" but with a wider job: signalling energy availability. It acts on the growth hormone secretagogue receptor type 1a (GHS-R1a) in the pituitary and hypothalamus, among other places. Ipamorelin mimics ghrelin at that receptor.

Two separate switches, not one. GHRH acts on the GHRH receptor — the switch CJC-1295 uses. Ghrelin acts on GHS-R1a through a partly different route: it amplifies the pituitary's response to GHRH and blunts somatostatin, the signal that suppresses GH release. This class presses the accelerator and eases the brake, which is why ipamorelin and a GHRH analogue are described as complementary.

The result is a pulse. Activating GHS-R1a triggers a burst of GH release, which raises IGF-1, the liver-derived growth factor that mediates much of GH's tissue action and is what clinicians actually measure. Ipamorelin's effect is short-lived — a pulse rather than a sustained elevation.

Why selectivity is the whole story — and what it does not settle. The older GHRPs stimulated GH but also drove ACTH and cortisol release, and raised prolactin. Chronic cortisol elevation is undesirable in almost any context: it works against lean tissue, impairs glucose handling and disturbs sleep. In the original studies ipamorelin released GH with potency comparable to GHRP-6 while not significantly raising cortisol, ACTH or prolactin — which is what "clean" means when you see the word used about it.

That is a real distinction, but be careful what it means. Selectivity says ipamorelin does less of something unwanted than an older compound that was itself never proven to deliver any clinical benefit. Being a tidier version of an unproven drug is a pharmacological improvement, not evidence that the drug works. Marketing deploys the selectivity claim as though it were an efficacy claim. It is not one.

Appetite comes with the territory. Because the target is the ghrelin receptor, appetite and gut-motility effects are not incidental side effects — they are the receptor doing its other jobs.

What the human evidence actually shows

The mechanism is established. The uses it is sold for are not.

Where the evidence comes from. The foundational work is preclinical: cell and animal studies establishing potency and the selectivity that defines the compound. That work is sound, and it is what the 1998 paper is cited for — but it is not human outcome evidence.

Ipamorelin did enter clinical development — and stopped. It was investigated in humans for postoperative ileus, the temporary shutdown of gut motility after abdominal surgery — a sensible indication given the receptor's role in motility. It was not carried through to registration, and no ipamorelin product is approved anywhere. A compound entering trials and not emerging as an approved therapy is unremarkable, but it is not a foundation for claiming benefit.

For the popular uses, there is no supporting human trial evidence. Fat loss, muscle gain, improved recovery, better sleep, anti-ageing — none has been demonstrated for ipamorelin in adequate human trials. What circulates online is preclinical extrapolation and anecdote.

Raising GH and IGF-1 is a biomarker, not an outcome. This is the central honesty problem for the whole GH-peptide category. A compound that moves a blood test has demonstrated it is pharmacologically active. Whether the person holding that result is stronger, leaner or recovering faster is a separate question, answered only by measuring those things in a trial. Medicine has a long record of drugs that moved surrogate markers persuasively and then failed to improve the outcomes the markers stood for. When a clinic shows you a rising IGF-1 result as proof of success, the question is: proof of what?

The CJC-1295 and ipamorelin stack has not been validated. It is the most promoted arrangement in this space, and the rationale — two receptors, complementary signals — is coherent. But no human outcome trial has evaluated the combination, for effectiveness or long-term safety. Two unproven compounds together make an unproven combination.

Where GHS-class drugs have been properly developed, they were approved narrowly — other ghrelin-receptor agonists have completed full development programmes for precise purposes, such as diagnosing adult growth hormone deficiency. That is what the evidence looks like when a compound in this class is actually proven for something. Nothing of the kind exists for ipamorelin.

Regulatory status in Australia

Ipamorelin is not on the Australian Register of Therapeutic Goods and is treated as a prescription-only (Schedule 4) substance. It has not been evaluated by the TGA, and there is no TGA-approved Product Information — no approved indications, no contraindications, no evaluated interaction data.

Where an Australian patient receives it, it is as a compounded preparation made for that individual against a prescription. That pathway is lawful; it is not registration, and the difference matters:

• The preparation has not been assessed by the TGA.
• Identity, purity, sterility and batch consistency depend entirely on the compounding pharmacy's quality systems.
• There is no post-market adverse-event surveillance of the kind registered medicines carry.

Anything supplied outside that pathway — offshore websites, "research use only" vendors, direct-to-consumer sellers — is unlawful for human use and unsafe, with no assurance of what the vial contains. See our explainers on peptide legality in Australia and compounded versus TGA-registered medicines. Prescription-only medicines may also not be advertised to the public here, so a compound like this being promoted to consumers with claimed benefits is not how the rules are meant to work.

Anti-doping status

Ipamorelin is prohibited at all times in sport under the WADA Prohibited List, category S2 — peptide hormones, growth factors and mimetics — which explicitly names growth hormone secretagogues. Sport Integrity Australia applies the same list. This binds every athlete under an anti-doping code, not only elite competitors, and applies whether or not the compound was prescribed.

Who it is being studied for — and who it is not for

Clinical interest in ghrelin-receptor agonists has centred on defined medical problems: gut motility disorders, cachexia and wasting syndromes, and the diagnosis of growth hormone deficiency. What these share is a measurable pathology and a testable outcome. Interest in ipamorelin for body composition, recovery, sleep and ageing in healthy adults is extrapolated from mechanism, not supported by trials.

Circumstances where a careful practitioner would be especially cautious, or would decline, include pregnancy and breastfeeding, active or previous cancer, diabetes or impaired glucose tolerance, untreated sleep apnoea, pituitary disease, and any history of disordered eating — the last because a compound acting on the appetite pathway is a poor idea for someone whose relationship with appetite is already the problem.

Two risks deserve emphasis. Glucose handling: growth hormone opposes insulin, and ghrelin-receptor activation has its own effects on glucose and insulin secretion, so anyone with diabetes or prediabetes sits in a different risk category. Cell proliferation: IGF-1 signalling drives cell growth and suppresses programmed cell death, which is why raising it in anyone with a current or past malignancy is a specialist conversation.

And the ordinary point. Poor recovery, fatigue and bad sleep have common, investigable causes — sleep apnoea, iron deficiency, thyroid dysfunction, depression, alcohol, chronic under-recovery in training. A practitioner who works through those before reaching for an unregistered peptide is doing the job properly. Our twelve questions to ask before any peptide protocol is written for that conversation.

Risks and considerations

Long-term human safety data do not exist, so the risk profile is incompletely characterised rather than reassuring. What is described comes from short studies, clinical experience, and what is known about the pathways involved. Reported and theoretically expected effects include:

• injection-site reactions — redness, itching, swelling, bruising
• headache, flushing and dizziness
• fluid retention and joint aches
• tiredness or altered sleep
• increased appetite, nausea, or changes in gut motility
• disturbance of blood-sugar regulation
• the theoretical IGF-1 and proliferation concern described above

Beyond side effects: it is an injectable, requiring competent technique and safe sharps handling, and product from outside the regulated supply chain adds impurity, mislabelling and sterility risks on top of the pharmacological ones. Anything unexpected goes to your treating practitioner promptly.

What to ask a doctor

• What problem are we treating, and how was that diagnosis reached?
• Have the common causes — sleep, iron, thyroid, mood, training load, alcohol — been investigated first?
• If growth hormone deficiency is raised, has it been properly tested by an endocrinologist?
• No trial has shown ipamorelin improves any real-world outcome. What is this recommendation based on?
• Are we treating my symptoms or my blood test, and what will you measure?
• What counts as this working, by when, and what is the stopping rule if it is not?
• Which pharmacy compounds it, and what quality accreditation do they hold?
• How will my blood sugar be monitored, and is my cancer history relevant here?
• If I compete in a tested sport, what does this do to my anti-doping status?
• What does the full course cost, including consultations, pathology and follow-up?

FAQ

Is ipamorelin legal to buy in Australia? It is prescription-only (Schedule 4) and not on the ARTG, so it cannot be bought over the counter or online. Lawful access is only via a registered practitioner's prescription, dispensed as a compounded preparation.

How is ipamorelin different from CJC-1295? Different receptors. Ipamorelin mimics ghrelin at GHS-R1a; CJC-1295 mimics GHRH at the GHRH receptor. Ipamorelin produces a short pulse; the DAC form of CJC-1295 acts over days. Both raise GH and IGF-1, and neither has been shown to improve a real-world outcome.

Why is ipamorelin described as "selective"? Because in the original research it raised GH without the cortisol, ACTH and prolactin increases seen with older GHRPs. That is a pharmacological distinction, not evidence of benefit — a cleaner version of a compound never proven to work is not itself proven.

Does it help with fat loss, muscle or anti-ageing? Unproven. There are no adequately designed human trials supporting those uses. What exists is preclinical work, mechanism-based reasoning and anecdote.

Will it make me hungry? It acts on the ghrelin receptor, so appetite effects are plausible and are reported by some users. This is a specific reason for caution in anyone with a history of disordered eating.

Is taking it the same as taking growth hormone? No. GH therapy supplies the hormone directly; ipamorelin asks your own pituitary to release a pulse. Both are prohibited in sport and both carry GH-related risks.

Should I look for a clinic that offers it? Start with the problem, not the compound. Find a practitioner who will investigate why you feel the way you do, tell you plainly what is unproven, and put a stopping rule on anything they do recommend. You can check a prescriber's AHPRA registration before any consultation, and compare doctor-supervised muscle and performance clinics once you know what you are looking for.